A Study of Carbon 13-based Deep Labelling of Bone Marrow Cells

N/AEnrolling By InvitationNCT07057583

Mayo Clinic40 enrolled

Overview

This study evaluates a novel laboratory method to study how certain bone marrow cells in the body take up nutrients from their environment.

PRIMARY OBJECTIVE: I. Evaluate differences in the amount of extracellular uptake of glucose and amino acids (AAs) between pre-malignant clonal plasma cells (cPCs) and polyclonal plasma cells (pPCs). OUTLINE: This is an observational study. Participants are assigned to 1 of 2 groups. GROUP I: Patients undergo blood collection and bone marrow aspiration as part of their standard care and have their medical records reviewed on study. GROUP II: Healthy volunteers undergo blood collection and bone marrow aspiration on study.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Monoclonal Gammopathy of Undetermined Significance (MGUS)Non-IgM Monoclonal Gammopathy of Undetermined Significance

Interventions

Non-Interventional StudyOTHER

Non-interventional study

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * All Participants: * At least age 18 years or older * Able to provide informed consent * MGUS Cohort: * International Myeloma Working Group (IMWG) criteria for the diagnosis of non-IgM MGUS Exclusion Criteria: * All Participants: * Unable to provide consent * Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) \>1 * Prior history of adverse events with conscious sedation * Ongoing use of immunosuppressive medications * All known pregnant and lactating women will be excluded

Locations (1)

Mayo Clinic in Rochester

Rochester, Minnesota, United States

Outcomes

Primary Outcomes

Extracellular uptake of glucose and amino acids (AAs) between pre-malignant clonal plasma cells (cPCs) and polyclonal plasma cells (pPCs)

Assessed by evaluating blood and bone marrow aspirate samples for mean 13Carbon (13C) percentage enrichment of the mass isotopomers of interest of at least 6 (i.e. the difference between a mean 13C percentage enrichment of a particular mass isotopomer is 12% in the MGUS group and 6% in the healthy participant group or vice versa) using a 2-group t-test with a 2-sided significance level of 0.01.

Time frame: Up to 30 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.